Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.
Phase 4
Completed
- Conditions
- Impotence
- Registration Number
- NCT00249730
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Brief Summary
To evaluate the efficacy of Viagra dose titration to 100mg versus 50mg in men with erectile dysfunction, based on responses to the IIEF questionnaire as measured at the beginning and at the end of double blind treatment, comparing the group titrated to 100mg vs. the group maintained on 50mg.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 510
Inclusion Criteria
- Documented clinical diagnosis of ED by using IIEF-EF domain with score of ≤ 25.
- Subjects must be in a stable relationship with the same partner for at least 6 months and willing to attempt sexual intercourse.
Exclusion Criteria
- Subjects in whom sexual activity is inadvisable in the opinion of the investigator such as significant cardiovascular disease in the last 6 months; including cardiac failure, myocardial infarction, unstable angina, stroke or transient ischemic attack (TIA), symptomatic or clinically significant cardiac arrhythmias including atrial fibrillation.
- Subjects who are currently taking or are likely to be treated with nitrates or nitric oxide donors in any form (oral, sublingual, buccal, transdermal, inhalational or as aerosols) on either regular or intermittent basis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in IIEF erectile function domain score at the end of double blind treatment.
- Secondary Outcome Measures
Name Time Method Change in other IIEF domain scores; Response to other questionnaires regarding treatment satisfaction, safety and tolerability.
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇬🇧Glasgow, United Kingdom